Индивидуальная оценка уровня простатического специфического антигена у больных раком предстательной железы после брахитерапии

1. Catalona W., Smith D., Ratliff T. et al. Measurement of prostate-specific antigen in serum a screening test for prostate cancer. N Engl J Med 1991;324: 1156—61.

2. Catalona W., Smith D., Ratliff T. et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948—54.

3. D’Amico A.V., Chen M.N., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125—35.

4. D’Amico A.V., Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72(9):2638—43.

5. Gebbaulet A., Potter R., Mazeron J.J. et al. The GEC ESTRO Handbook of brachytherapy. Belgium, ACCO; 2002.

6. Koutrouvelis P. Prostate cancer: What a man should know. URO-Radiology prostate institute, 2005.

7. Christensson A., Laurell B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755—63.

8. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7.

9. D’Amico A.V., Moul J.W., Carroll P.R. et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95(18):1376—83.

10. D’Amico A.V., Whittington R., Malkowicz S.D. et al. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:473—77.

11. Geist R.W. Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. J Urol 1995;45:1016—21.

12. Zagars G.K., von Eschenbach A.C. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538—48.